MCA
PTCT icon

McGuire Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

McGuire Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Sell
1,601
-5,291
-77% -$382K 0.07% 119
2026
Q1 		$470K Buy
6,892
+1,666
+32% +$118K 0.3% 52
2025
Q4 		$397K Buy
+5,226
New +$380K 0.25% 58

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

McGuire Capital Advisors's PTCT Position: Q2 2026 in Review

McGuire Capital Advisors reduced its PTC Therapeutics (PTCT) stake by 77% in Q2 2026, selling an estimated $382K and leaving 1,601 shares worth $131K. The position accounts for 0.07% of the portfolio, ranked #119.

McGuire Capital Advisors first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $470K in Q1 2026. 381 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • McGuire Capital Advisors held 1,601 shares of PTC Therapeutics worth $131K as of Q2 2026.
  • McGuire Capital Advisors sold 5,291 PTC Therapeutics shares in Q2 2026, an estimated $382K.
  • PTC Therapeutics made up 0.07% of McGuire Capital Advisors's portfolio in Q2 2026, its #119 holding.
  • McGuire Capital Advisors first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • McGuire Capital Advisors's PTC Therapeutics position peaked at $470K in Q1 2026.
  • 381 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.